Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.
There is a growing concern regarding the propensity of second generation antipsychotics (SGAs) to induce weight gain and metabolic adverse effects. Recent consensus guidelines have recommended assessment and monitoring procedures to appropriately detect and manage these adverse effects. This study addresses the appreciation and readiness of clinicians to implement management guidelines for these adverse effects. Respondents indicated awareness of the risks of treatment with SGAs. The extent of monitoring for metabolic adverse effects was low and inconsistent across measures and in frequency of evaluation. Ongoing efforts are needed to support and encourage change in clinician practice.
Buckley
Peter F
PF
Department of Psychiatry and Health Behavior, Medical College of Georgia, 1515 Pope Avenue, Augusta, GA 30912-3800, USA. pbuckley@mail.mcg.edu
Miller
Del D
DD
Singer
Beth
B
Arena
John
J
Stirewalt
Edna M
EM
D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D016903:Drug Monitoring; D006801:Humans; D008659:Metabolic Diseases / Q000139:chemically induced* / Q000145:classification; D021641:Recognition, Psychology / Q000187:drug effects*; D012196:Review Literature as Topic; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism*; D011795:Surveys and Questionnaires; D015430:Weight Gain / Q000187:drug effects*
D014150:Antipsychotic Agents